KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

West Pharmaceutical Services (WST) Cash from Operations (2016 - 2025)

Historic Cash from Operations for West Pharmaceutical Services (WST) over the last 17 years, with Q4 2025 value amounting to $251.1 million.

  • West Pharmaceutical Services' Cash from Operations rose 3208.84% to $251.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $754.8 million, marking a year-over-year increase of 1551.88%. This contributed to the annual value of $754.8 million for FY2025, which is 1551.88% up from last year.
  • West Pharmaceutical Services' Cash from Operations amounted to $251.1 million in Q4 2025, which was up 3208.84% from $197.2 million recorded in Q3 2025.
  • In the past 5 years, West Pharmaceutical Services' Cash from Operations registered a high of $251.1 million during Q4 2025, and its lowest value of $88.7 million during Q1 2021.
  • Over the past 5 years, West Pharmaceutical Services' median Cash from Operations value was $171.2 million (recorded in 2022), while the average stood at $174.6 million.
  • As far as peak fluctuations go, West Pharmaceutical Services' Cash from Operations skyrocketed by 7046.22% in 2022, and later crashed by 2172.97% in 2024.
  • Quarter analysis of 5 years shows West Pharmaceutical Services' Cash from Operations stood at $160.8 million in 2021, then soared by 43.53% to $230.8 million in 2022, then grew by 3.6% to $239.1 million in 2023, then decreased by 20.49% to $190.1 million in 2024, then skyrocketed by 32.09% to $251.1 million in 2025.
  • Its Cash from Operations stands at $251.1 million for Q4 2025, versus $197.2 million for Q3 2025 and $177.1 million for Q2 2025.